115 related articles for article (PubMed ID: 37792315)
61. Autocatalytic oncotherapy nanosystem with glucose depletion for the cascade amplification of hypoxia-activated chemotherapy and H
Hu Y; Bai S; Fan X; Zhou F; Chen B; Tan S; Xu H; Pan A; Liang S; He Y
Biomater Sci; 2022 May; 10(9):2358-2369. PubMed ID: 35383789
[TBL] [Abstract][Full Text] [Related]
62. Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
Li Y; Chen M; Yao B; Lu X; Zhang X; He P; Vasilatos SN; Ren X; Bian W; Yao C
J Mater Chem B; 2019 Oct; 7(38):5814-5824. PubMed ID: 31495855
[TBL] [Abstract][Full Text] [Related]
63. Engineering Stimuli-Activatable Boolean Logic Prodrug Nanoparticles for Combination Cancer Immunotherapy.
Hou B; Zhou L; Wang H; Saeed M; Wang D; Xu Z; Li Y; Yu H
Adv Mater; 2020 Mar; 32(12):e1907210. PubMed ID: 32048361
[TBL] [Abstract][Full Text] [Related]
64. Traceable Nanocluster-Prodrug Conjugate for Chemo-photodynamic Combinatorial Therapy of Non-small Cell Lung Cancer.
Srinivasulu YG; Mozhi A; Goswami N; Yao Q; Xie J
ACS Appl Bio Mater; 2021 Apr; 4(4):3232-3245. PubMed ID: 35014410
[TBL] [Abstract][Full Text] [Related]
65. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
Lai Y; Lu N; Luo S; Wang H; Zhang P
J Med Chem; 2022 Oct; 65(19):13041-13051. PubMed ID: 36134739
[TBL] [Abstract][Full Text] [Related]
66. Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy.
Jiang W; Wei L; Chen B; Luo X; Xu P; Cai J; Hu Y
J Nanobiotechnology; 2022 Mar; 20(1):129. PubMed ID: 35279133
[TBL] [Abstract][Full Text] [Related]
67. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy.
Hu X; Li R; Wu W; Fang K; Zhu Z; Wang Y; Zhou L; Chen M; Dong C; Shi S
J Control Release; 2022 Aug; 348():660-671. PubMed ID: 35716884
[TBL] [Abstract][Full Text] [Related]
68. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
69. Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer.
Zhu G; Wang K; Qin H; Zhao X; Chen W; Xu L; Cao W; Guo H
J Nanobiotechnology; 2020 Sep; 18(1):124. PubMed ID: 32887622
[TBL] [Abstract][Full Text] [Related]
70. A Paclitaxel Prodrug Activatable by Irradiation in a Hypoxic Microenvironment.
Zhou S; Hu X; Xia R; Liu S; Pei Q; Chen G; Xie Z; Jing X
Angew Chem Int Ed Engl; 2020 Dec; 59(51):23198-23205. PubMed ID: 32852145
[TBL] [Abstract][Full Text] [Related]
71. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
72. Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety.
Kuang X; Chi D; Li J; Guo C; Yang Y; Zhou S; Luo C; Liu H; He Z; Wang Y
Colloids Surf B Biointerfaces; 2021 Jul; 203():111766. PubMed ID: 33866279
[TBL] [Abstract][Full Text] [Related]
73. ROS-Activated homodimeric podophyllotoxin nanomedicine with self-accelerating drug release for efficient cancer eradication.
Liang B; Zhou D
Drug Deliv; 2021 Dec; 28(1):2361-2372. PubMed ID: 34747277
[TBL] [Abstract][Full Text] [Related]
74. Prodrug-loaded semiconducting polymer hydrogels for deep-tissue sono-immunotherapy of orthotopic glioblastoma.
Zhu L; Wang X; Ding M; Yu N; Zhang Y; Wu H; Zhang Q; Liu J; Li J
Biomater Sci; 2023 Oct; 11(20):6823-6833. PubMed ID: 37623749
[TBL] [Abstract][Full Text] [Related]
75. Dual Stimuli-Activatable Oxidative Stress Amplifying Agent as a Hybrid Anticancer Prodrug.
Han E; Kwon B; Yoo D; Kang C; Khang G; Lee D
Bioconjug Chem; 2017 Apr; 28(4):968-978. PubMed ID: 28192990
[TBL] [Abstract][Full Text] [Related]
76. Cyclic amplification of intracellular ROS boosts enzymatic prodrug activation for enhanced chemo-immunotherapy.
Liu Y; Jiang M; Zhao Z; Wang N; Wang K; Yuan Y
Acta Biomater; 2023 Aug; 166():567-580. PubMed ID: 37207741
[TBL] [Abstract][Full Text] [Related]
77. A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies.
Yao J; Li T; Shi X; Wang Y; Fang S; Wang H
Acta Biomater; 2021 Aug; 130():409-422. PubMed ID: 34087447
[TBL] [Abstract][Full Text] [Related]
78. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
79. A dual-amplified ROS-responsive nanosystem with self-accelerating drug release for synergistic chemotherapy.
Li J; Zong Q; Zhao Z; Yuan Y
Chem Commun (Camb); 2023 Mar; 59(21):3142-3145. PubMed ID: 36811610
[TBL] [Abstract][Full Text] [Related]
80. A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual-responsive and CD206 targeting to improve the anti-tumour effect.
Wang C; Jiao Y; Zhang X; Guo M; Zhang Q; Hu W; Dong S; Jakkree T; Lu Y; Wang J
IET Nanobiotechnol; 2023 Jul; 17(5):406-419. PubMed ID: 37055350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
